Cerebrovascular disease in maintenance hemodialysis patients: Results of the HEMO study

James A. Delmez, Guofen Yan, James Bailey, Gerald J. Beck, Srinivasan Beddhu, Alfred K. Cheung, George A. Kaysen, Andrew S. Levey, Mark J. Sarnak, Steve J. Schwab

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Background: Cerebrovascular disease (CBVD) in hemodialysis patients is associated with significant morbidity and mortality. A secondary analysis of CBVD in the Hemodialysis (HEMO) Study was performed. Specific objectives were to: (1) determine risk factors for the presence of CBVD at baseline, (2) assess risk factors for the subsequent occurrence of cerebrovascular deaths, and (3) analyze the effects of dose and flux on cerebrovascular mortality. Methods: The HEMO Study was a randomized multicenter study evaluating the effects of high-dose versus standard-dose and high-flux versus low-flux hemodialysis. There were 1,846 patients enrolled, with a mean follow-up of 2.84 years. Results: Factors associated with the baseline presence of CBVD included age (P < 0.0001), presence of any cardiac disease (P < 0.0001), and diabetes mellitus (P < 0.0001). There were 65 deaths caused by CBVD (event rate, 1.2/100 patient-years). Multivariate Cox regression using a backward-variables selection procedure showed that diabetes, lower albumin level, greater hematocrit, and lower body mass index at baseline were associated significantly with subsequent CBVD death. There was no effect of flux or dose on overall rate of CBVD deaths. However, an interaction was found between baseline CBVD status and flux intervention on CBVD death (P = 0.016). In the subgroup of patients without the baseline presence of CBVD, high-flux dialysis was associated with a lower risk for death caused by CBVD (P = 0.016). A borderline interaction between years of dialysis therapy and flux on subsequent CBVD death was detected (P = 0.05). The beneficial effect of high flux was evident in those on hemodialysis therapy for longer than 3.7 years (P = 0.012). Conclusion: High flux was associated with decreased CBVD mortality in those without known CBVD at baseline and those on hemodialysis therapy for longer than 3.7 years. This secondary analysis strengthens, but does not prove, the hypothesis that high-flux treatment may attenuate the death rate from vascular disease.

Original languageEnglish (US)
Pages (from-to)131-138
Number of pages8
JournalAmerican Journal of Kidney Diseases
Volume47
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

Cerebrovascular Disorders
Renal Dialysis
Maintenance
Mortality
Dialysis
Therapeutics
Vascular Diseases
Hematocrit

Keywords

  • Adequacy
  • Cerebrovascular disease
  • Clinical trial
  • Flux
  • HEMO Study
  • Hemodialysis
  • Membranes
  • Mortality

ASJC Scopus subject areas

  • Nephrology

Cite this

Delmez, J. A., Yan, G., Bailey, J., Beck, G. J., Beddhu, S., Cheung, A. K., ... Schwab, S. J. (2006). Cerebrovascular disease in maintenance hemodialysis patients: Results of the HEMO study. American Journal of Kidney Diseases, 47(1), 131-138. https://doi.org/10.1053/j.ajkd.2005.09.031

Cerebrovascular disease in maintenance hemodialysis patients : Results of the HEMO study. / Delmez, James A.; Yan, Guofen; Bailey, James; Beck, Gerald J.; Beddhu, Srinivasan; Cheung, Alfred K.; Kaysen, George A.; Levey, Andrew S.; Sarnak, Mark J.; Schwab, Steve J.

In: American Journal of Kidney Diseases, Vol. 47, No. 1, 01.2006, p. 131-138.

Research output: Contribution to journalArticle

Delmez, JA, Yan, G, Bailey, J, Beck, GJ, Beddhu, S, Cheung, AK, Kaysen, GA, Levey, AS, Sarnak, MJ & Schwab, SJ 2006, 'Cerebrovascular disease in maintenance hemodialysis patients: Results of the HEMO study', American Journal of Kidney Diseases, vol. 47, no. 1, pp. 131-138. https://doi.org/10.1053/j.ajkd.2005.09.031
Delmez, James A. ; Yan, Guofen ; Bailey, James ; Beck, Gerald J. ; Beddhu, Srinivasan ; Cheung, Alfred K. ; Kaysen, George A. ; Levey, Andrew S. ; Sarnak, Mark J. ; Schwab, Steve J. / Cerebrovascular disease in maintenance hemodialysis patients : Results of the HEMO study. In: American Journal of Kidney Diseases. 2006 ; Vol. 47, No. 1. pp. 131-138.
@article{05422353e31c4453bd56e56439e505cc,
title = "Cerebrovascular disease in maintenance hemodialysis patients: Results of the HEMO study",
abstract = "Background: Cerebrovascular disease (CBVD) in hemodialysis patients is associated with significant morbidity and mortality. A secondary analysis of CBVD in the Hemodialysis (HEMO) Study was performed. Specific objectives were to: (1) determine risk factors for the presence of CBVD at baseline, (2) assess risk factors for the subsequent occurrence of cerebrovascular deaths, and (3) analyze the effects of dose and flux on cerebrovascular mortality. Methods: The HEMO Study was a randomized multicenter study evaluating the effects of high-dose versus standard-dose and high-flux versus low-flux hemodialysis. There were 1,846 patients enrolled, with a mean follow-up of 2.84 years. Results: Factors associated with the baseline presence of CBVD included age (P < 0.0001), presence of any cardiac disease (P < 0.0001), and diabetes mellitus (P < 0.0001). There were 65 deaths caused by CBVD (event rate, 1.2/100 patient-years). Multivariate Cox regression using a backward-variables selection procedure showed that diabetes, lower albumin level, greater hematocrit, and lower body mass index at baseline were associated significantly with subsequent CBVD death. There was no effect of flux or dose on overall rate of CBVD deaths. However, an interaction was found between baseline CBVD status and flux intervention on CBVD death (P = 0.016). In the subgroup of patients without the baseline presence of CBVD, high-flux dialysis was associated with a lower risk for death caused by CBVD (P = 0.016). A borderline interaction between years of dialysis therapy and flux on subsequent CBVD death was detected (P = 0.05). The beneficial effect of high flux was evident in those on hemodialysis therapy for longer than 3.7 years (P = 0.012). Conclusion: High flux was associated with decreased CBVD mortality in those without known CBVD at baseline and those on hemodialysis therapy for longer than 3.7 years. This secondary analysis strengthens, but does not prove, the hypothesis that high-flux treatment may attenuate the death rate from vascular disease.",
keywords = "Adequacy, Cerebrovascular disease, Clinical trial, Flux, HEMO Study, Hemodialysis, Membranes, Mortality",
author = "Delmez, {James A.} and Guofen Yan and James Bailey and Beck, {Gerald J.} and Srinivasan Beddhu and Cheung, {Alfred K.} and Kaysen, {George A.} and Levey, {Andrew S.} and Sarnak, {Mark J.} and Schwab, {Steve J.}",
year = "2006",
month = "1",
doi = "10.1053/j.ajkd.2005.09.031",
language = "English (US)",
volume = "47",
pages = "131--138",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Cerebrovascular disease in maintenance hemodialysis patients

T2 - Results of the HEMO study

AU - Delmez, James A.

AU - Yan, Guofen

AU - Bailey, James

AU - Beck, Gerald J.

AU - Beddhu, Srinivasan

AU - Cheung, Alfred K.

AU - Kaysen, George A.

AU - Levey, Andrew S.

AU - Sarnak, Mark J.

AU - Schwab, Steve J.

PY - 2006/1

Y1 - 2006/1

N2 - Background: Cerebrovascular disease (CBVD) in hemodialysis patients is associated with significant morbidity and mortality. A secondary analysis of CBVD in the Hemodialysis (HEMO) Study was performed. Specific objectives were to: (1) determine risk factors for the presence of CBVD at baseline, (2) assess risk factors for the subsequent occurrence of cerebrovascular deaths, and (3) analyze the effects of dose and flux on cerebrovascular mortality. Methods: The HEMO Study was a randomized multicenter study evaluating the effects of high-dose versus standard-dose and high-flux versus low-flux hemodialysis. There were 1,846 patients enrolled, with a mean follow-up of 2.84 years. Results: Factors associated with the baseline presence of CBVD included age (P < 0.0001), presence of any cardiac disease (P < 0.0001), and diabetes mellitus (P < 0.0001). There were 65 deaths caused by CBVD (event rate, 1.2/100 patient-years). Multivariate Cox regression using a backward-variables selection procedure showed that diabetes, lower albumin level, greater hematocrit, and lower body mass index at baseline were associated significantly with subsequent CBVD death. There was no effect of flux or dose on overall rate of CBVD deaths. However, an interaction was found between baseline CBVD status and flux intervention on CBVD death (P = 0.016). In the subgroup of patients without the baseline presence of CBVD, high-flux dialysis was associated with a lower risk for death caused by CBVD (P = 0.016). A borderline interaction between years of dialysis therapy and flux on subsequent CBVD death was detected (P = 0.05). The beneficial effect of high flux was evident in those on hemodialysis therapy for longer than 3.7 years (P = 0.012). Conclusion: High flux was associated with decreased CBVD mortality in those without known CBVD at baseline and those on hemodialysis therapy for longer than 3.7 years. This secondary analysis strengthens, but does not prove, the hypothesis that high-flux treatment may attenuate the death rate from vascular disease.

AB - Background: Cerebrovascular disease (CBVD) in hemodialysis patients is associated with significant morbidity and mortality. A secondary analysis of CBVD in the Hemodialysis (HEMO) Study was performed. Specific objectives were to: (1) determine risk factors for the presence of CBVD at baseline, (2) assess risk factors for the subsequent occurrence of cerebrovascular deaths, and (3) analyze the effects of dose and flux on cerebrovascular mortality. Methods: The HEMO Study was a randomized multicenter study evaluating the effects of high-dose versus standard-dose and high-flux versus low-flux hemodialysis. There were 1,846 patients enrolled, with a mean follow-up of 2.84 years. Results: Factors associated with the baseline presence of CBVD included age (P < 0.0001), presence of any cardiac disease (P < 0.0001), and diabetes mellitus (P < 0.0001). There were 65 deaths caused by CBVD (event rate, 1.2/100 patient-years). Multivariate Cox regression using a backward-variables selection procedure showed that diabetes, lower albumin level, greater hematocrit, and lower body mass index at baseline were associated significantly with subsequent CBVD death. There was no effect of flux or dose on overall rate of CBVD deaths. However, an interaction was found between baseline CBVD status and flux intervention on CBVD death (P = 0.016). In the subgroup of patients without the baseline presence of CBVD, high-flux dialysis was associated with a lower risk for death caused by CBVD (P = 0.016). A borderline interaction between years of dialysis therapy and flux on subsequent CBVD death was detected (P = 0.05). The beneficial effect of high flux was evident in those on hemodialysis therapy for longer than 3.7 years (P = 0.012). Conclusion: High flux was associated with decreased CBVD mortality in those without known CBVD at baseline and those on hemodialysis therapy for longer than 3.7 years. This secondary analysis strengthens, but does not prove, the hypothesis that high-flux treatment may attenuate the death rate from vascular disease.

KW - Adequacy

KW - Cerebrovascular disease

KW - Clinical trial

KW - Flux

KW - HEMO Study

KW - Hemodialysis

KW - Membranes

KW - Mortality

UR - http://www.scopus.com/inward/record.url?scp=29244443414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29244443414&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2005.09.031

DO - 10.1053/j.ajkd.2005.09.031

M3 - Article

C2 - 16377394

AN - SCOPUS:29244443414

VL - 47

SP - 131

EP - 138

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 1

ER -